The study explores the interconnected risks between COVID-19 and Alzheimer’s Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.
Santhera and Catalyst to market DMD drug vamorolone in North America – Pharmaceutical Technology
Santhera plan to repay its debt of CHF 29m ($33.8m) to Highbridge Capital and fund the pre-commercialization and launch of vamorolone in Europe. Image Credit:
July 19, 2023